陕西康惠制药股份有限公司 关于业绩补偿事项申请仲裁的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 证券代码：603139 证券简称：康惠股份 公告编号：2025-075 重要内容提示： ● 案件所处的仲裁阶段：咸阳仲裁委员会已受理 ● 上市公司所处的当事人地位：仲裁申请人 ● 涉案的金额：26,629.42 万元及本案仲裁费用 ● 是否会对上市公司损益产生影响：鉴于案件尚未开庭审理，仲裁结果存 在不确定性，暂无法判断对公司本期或期后利润影响。 一、业绩补偿事项的基本情况 2020 年 9 月，公司以 3264 万元收购来新胜所持山东友帮生化科技有限公司 （以下简称"山东友帮"）51%的股权，来新胜承诺山东友帮 2021-2023 年度实现 的净利润（以扣除非经常性损益前后的净利润孰低值为准）分别不低于 500 万元、 1000 万元、2000 万元，在公司 2023 年度审计报告出具后，若山东友帮 2021 年 度至 2023 年度累计实际净利润数低于承诺净利润数（即 3500 万元），则由来新 胜一次性对公司进行现金 ...

Core Viewpoint - 康惠制药 is pursuing arbitration against 来新胜 for failing to meet profit commitments related to the acquisition of 山东友帮, with a significant compensation amount still owed [1] Summary by Relevant Sections Acquisition Details - 康惠制药 acquired 51% of 山东友帮 from 来新胜 for 32.64 million yuan in September 2020 [1] - 来新胜 committed to a cumulative net profit of no less than 35 million yuan from 2021 to 2023 [1] Performance and Compensation - 山东友帮 did not meet the promised performance, leading to a compensation obligation of 269 million yuan from 来新胜 [1] - As of now, 来新胜 still owes 266 million yuan after paying 2.8 million yuan in compensation [1] Legal Proceedings - 康惠制药 has applied for arbitration with the 咸阳仲裁委, which was accepted on November 13 [1] - The case has not yet gone to court, making it difficult to assess the impact on the company's profits [1]

Core Viewpoint - Kanghui Co., Ltd. has shown a significant stock price increase of 64.07% year-to-date, indicating strong market interest and potential growth in the pharmaceutical sector [2]. Financial Performance - As of September 30, Kanghui Co., Ltd. reported a revenue of 356 million yuan, a year-on-year decrease of 11.97%, and a net profit attributable to shareholders of -133 million yuan, reflecting a substantial decline of 246.07% [2]. - The company has cumulatively distributed 54.23 million yuan in dividends since its A-share listing, with no dividends paid in the last three years [3]. Stock Market Activity - The stock price of Kanghui Co., Ltd. rose by 2.04% on November 11, reaching 23.56 yuan per share, with a trading volume of 23.57 million yuan and a turnover rate of 1.01% [1]. - The stock has appeared on the "Dragon and Tiger List" five times this year, with the most recent instance on June 16, where it recorded a net purchase of 7.7 million yuan [2]. Shareholder Information - As of September 30, the number of shareholders for Kanghui Co., Ltd. was 9,458, a decrease of 21.15% from the previous period, while the average circulating shares per person increased by 26.82% to 10,560 shares [2]. Business Overview - Kanghui Co., Ltd., established on December 24, 2009, and listed on April 21, 2017, is primarily engaged in the research, development, production, and sales of traditional Chinese medicine, with its main business revenue composition being 60.68% from pharmaceutical manufacturing and 36.79% from pharmaceutical distribution [2]. - The company operates within the pharmaceutical and biotechnology sector, specifically in the traditional Chinese medicine sub-sector [2].

股票简称：康惠股份 股票代码：603139 2025 年第三次临时股东会 会议资料 陕西康惠制药股份有限公司 康惠股份 2025 年第三次临时股东会会议资料 目 录 | 2025 | 年第三次临时股东会会议须知 - | 1 | - | | --- | --- | --- | --- | | 2025 | 年第三次临时股东会会议议程 - | 3 | - | | 2025 | 年第三次临时股东会会议议案 - | 4 | - | | 议案一 | 关于对应收款项单项计提坏账准备的议案 | - 4 | - | 康惠股份 2025 年第三次临时股东会会议资料 陕西康惠制药股份有限公司 2025 年第三次临时股东会会议须知 2025 年 11 月 为维护全体股东的合法权益，确保股东会的正常秩序和议事效率，保证股东会的顺利进 行，根据《公司法》、《公司章程》及公司《股东会议事规则》等法律法规的有关规定，特制 定本须知，请出席股东会的全体人员遵照执行。 一、本次会议期间，全体出席会议人员应以维护股东合法权益，确保会议正常进行，提 高议事效率为原则，认真履行法定义务。 二、为保证本次会议的严肃性和正常秩序，切实维护股东的合法权益 ...

Core Points - The company announced an increase in capital for its wholly-owned subsidiary, Beijing Kanghui Zhichuang Technology Co., Ltd., amounting to RMB 90 million [2] - Following the capital increase, the registered capital of the subsidiary will rise from RMB 10 million to RMB 100 million [2] - The company will maintain 100% ownership of the subsidiary after the capital increase [2]

证券代码：603139 证券简称：康惠股份 公告编号：2025-074 陕西康惠制药股份有限公司 关于全资子公司完成工商变更登记的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 陕西康惠制药股份有限公司（以下简称"公司"）于 2025 年 10 月 29 日召开 了第六届董事会第三次会议，审议通过了《关于向全资子公司增资的议案》，同 意公司以自有或自筹资金的方式向北京康惠智创科技有限公司（以下简称"康惠 智创"）增资人民币 9,000 万元。本次增加注册资本后，公司仍直接持有康惠智 创 100%股权。具体内容详见公司在上海证券交易所网站（www.sse.com.cn）披 露的《关于向全资子公司增资的公告》（公告编号：2025-067）。 近日，康惠智创就上述增资事宜向北京市朝阳区市场监督管理局申请办理了 工商变更手续，并取得了北京市朝阳区市场监督管理局换发的《营业执照》，注 册资本由人民币 1,000 万元变更为人民币 10,000 万元。除前述注册资本变更外， 康惠智创其他登记事项均未发生变更。变更后的登记信息如下： ...

Core Points - The announcement details the results of GMP compliance inspections for two pharmaceutical companies in Shaanxi Province, confirming that both companies meet the required standards [1] Group 1: Company Inspections - Shaanxi Baiyun Pharmaceutical Co., Ltd. was inspected from September 9 to September 12, 2025, and was found to be compliant with GMP requirements [1] - Shaanxi Jingyang Jinlan Skin Disease Research Institute and Shaanxi Kanghui Pharmaceutical Co., Ltd. were inspected on July 22, 2025, and from July 30 to August 1, 2025, respectively, and both were also found to be compliant with GMP requirements [1]

证券代码：603139 证券简称：康惠股份 公告编号：2025-073 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 近日，陕西康惠制药股份有限公司（以下简称"公司"）获得陕西省药品监 督管理局许可，同意公司《药品生产许可证》（许可证编号：陕 20160073）法定 代表人由"王延岭"变更为"李红明"，企业负责人由"王延岭"变更为"WANG JING"，其他内容不变，具体情况如下： 一、《药品生产许可证》的主要信息 企业名称：陕西康惠制药股份有限公司 许可证编号：陕 20160073 社会信用代码：916100006984144239 分类码：AhzCz 注册地址：陕西省咸阳市秦都区高新技术产业开发区彩虹二路 法定代表人：李红明 陕西康惠制药股份有限公司 关于变更药品生产许可证的公告 生产负责人：郭建刚 有效期至：2030 年 8 月 24 日 生产地址和生产范围： 陕西省咸阳市秦都区高新技术产业开发区胭脂路 36 号：膏药，软膏剂，茶 剂，颗粒剂，硬胶囊剂，片剂，酒剂，合剂，搽剂，酊剂，洗剂； 陕西省咸阳市秦都区高新开发区 ...

Company Overview - Kanghui Co., Ltd. is located in Xi'an, Shaanxi Province, established on December 24, 2009, and listed on April 21, 2017. The company is primarily engaged in the research, development, production, and sales of traditional Chinese medicine [1][2] - The main business revenue composition includes: pharmaceutical manufacturing 60.68%, pharmaceutical distribution 36.79%, and others 2.53% [1] Stock Performance - As of October 31, Kanghui's stock price increased by 2.00%, reaching 22.40 CNY per share, with a total market capitalization of 2.237 billion CNY [1] - Year-to-date, the stock price has risen by 55.99%, but it has seen a decline of 2.01% over the last five trading days, 0.18% over the last 20 days, and 0.13% over the last 60 days [1] - The company has appeared on the "Dragon and Tiger List" five times this year, with the most recent appearance on June 16, where it recorded a net purchase of 7.7 million CNY [1] Financial Performance - For the period from January to September 2025, Kanghui reported a revenue of 356 million CNY, a year-on-year decrease of 11.97%, and a net profit attributable to shareholders of -133 million CNY, a significant year-on-year decrease of 246.07% [2] - The company has cumulatively distributed 54.2348 million CNY since its A-share listing, with no distributions made in the last three years [3] Shareholder Information - As of September 30, the number of shareholders for Kanghui was 9,458, a decrease of 21.15% from the previous period, while the average circulating shares per person increased by 26.82% to 10,560 shares [2] Industry Classification - Kanghui is classified under the pharmaceutical and biological industry, specifically in the traditional Chinese medicine sector, and is associated with concepts such as Helicobacter pylori, pharmaceutical e-commerce, hepatitis treatment, traditional Chinese medicine, and NMN [2]

Core Viewpoint - Kanghui Co., Ltd. is a well-known Chinese traditional Chinese medicine enterprise with strong technical capabilities in drug research and production, facing challenges in revenue and profitability compared to industry peers [1][2]. Group 1: Company Overview - Kanghui Co., Ltd. was established on December 24, 2009, and listed on the Shanghai Stock Exchange on April 21, 2017, with its registered and office locations in Xi'an, Shaanxi Province [1]. - The company engages in the research, development, production, and sales of traditional Chinese medicine, classified under the pharmaceutical and biological industry [1]. Group 2: Financial Performance - For Q3 2025, Kanghui's revenue was 356 million yuan, ranking 60th out of 69 companies in the industry, while the industry leader, Baiyunshan, reported revenue of 61.606 billion yuan [2]. - The company's net profit for the same period was -157 million yuan, placing it 66th in the industry, with the top performer, Yunnan Baiyao, achieving a net profit of 4.789 billion yuan [2]. Group 3: Financial Ratios - As of Q3 2025, Kanghui's debt-to-asset ratio was 60.48%, an increase from 51.46% in the previous year, significantly higher than the industry average of 32.81% [3]. - The gross profit margin for Q3 2025 was 26.45%, down from 32.15% year-on-year, and below the industry average of 52.44% [3]. Group 4: Shareholder Information - As of September 30, 2025, the number of A-share shareholders decreased by 21.15% to 9,458, while the average number of circulating A-shares held per shareholder increased by 26.82% to 10,600 [5].